|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
4.26(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,642 |
52
Week Range: |
$23.21 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
10,417 |
15,666 |
48,238 |
96,962 |
Total Sell Value |
$292,740 |
$454,291 |
$1,411,373 |
$2,911,362 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
3 |
6 |
8 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
|
2017-05-28 |
4 |
D |
$57.70 |
$101,841 |
D/D |
(1,765) |
56,889 |
|
- |
|
Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
58,654 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-05-28 |
4 |
D |
$57.70 |
$67,913 |
D/D |
(1,177) |
129,477 |
|
- |
|
Frates James M |
SVP, Alks Inc; CFO ALKS |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
130,654 |
|
- |
|
Stejbach Mark |
SVP/Chief Comm Off, Alks Inc |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
44,013 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-28 |
4 |
D |
$57.70 |
$373,319 |
D/D |
(6,470) |
637,686 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,750 |
644,156 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-28 |
4 |
D |
$57.70 |
$67,913 |
D/D |
(1,177) |
163,693 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
164,870 |
|
- |
|
Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
|
2017-05-28 |
4 |
D |
$57.70 |
$23,426 |
D/D |
(406) |
31,157 |
|
- |
|
Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
31,563 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2017-05-28 |
4 |
D |
$57.70 |
$172,523 |
D/D |
(2,990) |
74,708 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,750 |
77,698 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-24 |
4 |
AS |
$57.42 |
$1,435,535 |
D/D |
(25,000) |
630,406 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-24 |
4 |
OE |
$15.95 |
$398,750 |
D/D |
25,000 |
655,406 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-18 |
4 |
AS |
$57.14 |
$572,254 |
D/D |
(10,000) |
162,370 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-18 |
4 |
OE |
$15.95 |
$159,500 |
D/D |
10,000 |
172,370 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-17 |
4 |
AS |
$57.23 |
$2,909,439 |
D/D |
(50,000) |
630,406 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-17 |
4 |
OE |
$15.95 |
$797,500 |
D/D |
50,000 |
680,406 |
|
- |
|
Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
|
2017-05-17 |
4 |
OE |
$15.95 |
$35,888 |
D/D |
2,250 |
30,313 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-11 |
4 |
AS |
$57.01 |
$570,082 |
D/D |
(10,000) |
162,370 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2017-05-11 |
4 |
OE |
$15.95 |
$159,500 |
D/D |
10,000 |
172,370 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-10 |
4 |
AS |
$57.12 |
$1,432,244 |
D/D |
(25,000) |
630,406 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2017-05-10 |
4 |
OE |
$15.95 |
$398,750 |
D/D |
25,000 |
655,406 |
|
- |
|
Cooke Shane |
President, Alkermes plc |
|
2017-05-04 |
4 |
AS |
$60.05 |
$390,328 |
D/D |
(6,500) |
71,948 |
|
- |
|
2018 Records found
|
|
Page 30 of 81 |
|
|